CONMED (CNMD)
(Delayed Data from NYSE)
$61.90 USD
-8.11 (-11.58%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $61.89 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$61.90 USD
-8.11 (-11.58%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $61.89 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth B Momentum B VGM
Zacks News
CONMED (CNMD) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) adjusted first-quarter earnings and revenues beat estimates on the back of strong U.S. and International markets as well as supply-chain improvement.
Conmed (CNMD) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 6.76% and 1.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Smith+Nephew (SNN) Expands in Australia With New Alliance
by Zacks Equity Research
The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
CONMED (CNMD) Misses on Q4 Earnings, Beats Revenue Estimates
by Zacks Equity Research
CONMED's (CNMD) adjusted fourth-quarter earnings misses while sales beat estimates on the back of strong growth in the United States and international markets. Gross margin improves with a rise in sales.
Here's What Key Metrics Tell Us About Conmed (CNMD) Q4 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Conmed (CNMD) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of -4.51% and 1.77%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Earnings on Feb 1: RVTY, CAH & More
by Debanjana Dey
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how CAH, RVTY, CNMD, SRDX and BDX are placed ahead of their earnings releases.
Ahead of Conmed (CNMD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Conmed (CNMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Align Technology (ALGN) Moves 11.1% Higher: Will This Strength Last?
by Zacks Equity Research
Align Technology (ALGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Conmed (CNMD) Up 14.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
CNMD or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CNMD vs. ALGN: Which Stock Is the Better Value Option?
CONMED (CNMD) Beats on Q3 Earnings, Ups '23 EPS View
by Zacks Equity Research
CONMED's (CNMD) adjusted third-quarter earnings and sales beat estimates on the back of strong growth in the U.S and international markets. Gross margin improves.
Conmed (CNMD) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Conmed (CNMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 8.43% and 1.12%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?
by Zacks Equity Research
Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Conmed (CNMD) have performed compared to their sector so far this year.
Here's Why You Should Add McKesson (MCK) to Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
CNMD vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
CNMD vs. ALGN: Which Stock Is the Better Value Option?
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Conmed (CNMD) have performed compared to their sector so far this year.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.